Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study

Sebastiano Buti, Melissa Bersanelli, Alessandro Viansone, Alessandro Leonetti, Cristina Masini, Raffaele Ratta, Giuseppe Procopio, Francesca Maines, Roberto Iacovelli, Chiara Ciccarese, Maria Giuseppa Vitale, Ugo De Giorgi, Claudia Mucciarini, Marco Maruzzo, Giuseppe Prati, Elisabetta Lattanzi, Patrizia Ciammella, Alessio Bruni, Stefano Andreani, Nunziata D'Abbiero

Research output: Contribution to journalArticle

Abstract

Objectives: stereotactic body radiation therapy (SBRT) use has increased overtime for the management of metastatic renal cell carcinoma (mRCC) patients, with a likely good control of irradiated lesions. We planned a retrospective multicenter Italian study, with the aim of investigating the outcome of treatment with SBRT for non-brain secondary lesions in mRCC patients. Methods: all consecutive metastatic non-brain lesions from mRCC that underwent SBRT at nine Italian institutions from January 2015 to June 2017 were considered. The primary endpoint of the study was the lesion-PFS, calculated from SBRT initiation to the local progression of the irradiated lesion. Results: 57 extracranial metastatic lesions from 48 patients with primary mRCC were treated with SBRT. At the median follow-up of 26.4 months, the median lesion-PFS was not reached (43 censored); 72.4% of lesions were progression-free at 40 months, with significantly better lesion-PFS for small metastatic lesions (<14 mm). SBRT was safe and the 1-year local disease control was 87.7%. After SBRT, 18 patients (37.5%) permanently interrupted systemic therapy. Conclusions: consistently with the previous literature, our findings support the use of SBRT in selected mRCC patients.

Original languageEnglish
Article number100161
JournalCancer Treatment and Research Communications
Volume22
DOIs
Publication statusPublished - 2020

    Fingerprint

Keywords

  • Extra-cranial
  • Metastatic renal cell carcinoma
  • Oligometastatic
  • Oligoprogressive
  • RCC
  • SBRT
  • Stereotactic radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this